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Abstract
Background: Bone status in HIV-infected patients on antiretroviral treatment (ART) is poorly documented in resource-
limited settings. We compared bone mineral density between HIV-infected patients and control subjects from Dakar,
Senegal.
Methods: A total of 207 (134 women and 73 men) HIV-infected patients from an observational cohort in Dakar (ANRS 1215)
and 207 age- and sex-matched controls from the general population were enrolled. Bone mineral density was assessed by
quantitative ultrasound (QUS) at the calcaneus, an alternative to the reference method (i.e. dual X-absorptiometry), often
not available in resource-limited countries.
Results: Mean age was 47.0 (68.5) years. Patients had received ART for a median duration of 8.8 years; 45% received a
protease inhibitor and 27% tenofovir; 84% had undetectable viral load. Patients had lower body mass index (BMI) than
controls (23 versus 26 kg/m
2,P ,0.001). In unadjusted analysis, QUS bone mineral density was lower in HIV-infected patients
than in controls (difference: 20.36 standard deviation, 95% confidence interval (CI): 20.59;20.12, P=0.003). Adjusting for
BMI, physical activity, smoking and calcium intake attenuated the difference (20.27, CI: 20.53;20.002, P=0.05). Differences
in BMI between patients and controls explained a third of the difference in QUS bone mineral density. Among patients, BMI
was independently associated with QUS bone mineral density (P,0.001). An association between undetectable viral load
and QUS bone density was also suggested (b=0.48, CI: 0.02;0.93; P=0.04). No association between protease inhibitor or
tenofovir use and QUS bone mineral density was found.
Conclusion: Senegalese HIV-infected patients had reduced QUS bone mineral density in comparison with control subjects,
in part related to their lower BMI. Further investigation is needed to clarify the clinical significance of these observations.
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Introduction
Reduced bone mineral density is a recognized metabolic
complication of HIV and its treatment. The prevalence of
osteoporosis is estimated to be around threefold-higher in HIV-
infected individuals than in uninfected controls [1,2]. Several
studies indicate that HIV infection is also associated with increased
though modest risk of fracture [3,4]. Despite growing concern
about this complication, the impact on bones of HIV and its
treatment in resource-limited countries is poorly documented. To
our knowledge, no study has been conducted on this subject in
Sub-Saharan Africa, although this region houses two-thirds of the
persons living with HIV worldwide. This situation is primarily due
to the lack of specific equipment for assessing bone mineral density
by dual-energy x-ray absorptiometry (DXA). DXA is the standard
reference method for diagnosing osteoporosis, but requires
expensive equipment not currently available in most resource-
constrained regions. Meanwhile, recent developments in densi-
tometry technology have provided alternative methods, among
which heel quantitative ultrasound (QUS) appears to be the most
widely used [5]. It is inexpensive, portable, ionizing-radiation-free
and proven to predict hip fractures and all osteoporotic fractures
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Although its use in clinical practice is still not well defined and
depends on the type of device; for epidemiological purposes, it
provides an appropriate tool for comparing bone mineral density
between different groups and identifying factors associated with
variation in bone density, especially in settings where DXA is not
available [10,11].
The first objective of this study was to compare QUS bone
density between HIV-infected patients initially included in an
observational cohort (ANRS 1215) in the city of Dakar, Senegal,
and a group of age- and sex-matched control subjects from the
general population of Dakar. A second objective was to assess the
effect of traditional and HIV-related factors on QUS bone mineral
density in HIV-infected patients.
Methods
Study design
A cross-sectional exposed/unexposed study was conducted in
Dakar, Senegal in 2010. Each HIV-infected patient (exposed) was
matched for sex, age (+/25 years) and living area to a control
subject (unexposed) from the general population.
Study population
HIV-infected patients were recruited within the ANRS 1215
observational cohort which initially included 404 HIV-1 patients
enrolled in the Senegalese antiretroviral drug access initiative
between 1998 and 2002 [12,13,14]. Forty patients enrolled in a
subsequent clinical trial in 2004 were later pooled into the ANRS
1215 cohort [15]. All patients were receiving antiretroviral
treatment (ART). The initial ART regimen was a triple drug
combination: two nucleoside reverse transcriptase inhibitors
(NRTI) + a non-nucleoside reverse transcriptase inhibitor
(NNRTI) or a protease inhibitor (PI), except for 18 patients who
received only two NRTIs.
Participants
Among the 444 patients included in the ANRS 1215 cohort,
125 had died and 52 were lost-to-follow-up. Finally, a total of 267
patients who were still alive and followed on June, 30
th, 2010 at
the Fann University Hospital in Dakar were eligible.
Patients were recruited between April and June 2010 during
clinical follow-up visits. Among 231 patients who presented for
routine examination and were invited to join, 218 agreed to
participate and were enrolled. Patient clinical and biological
characteristics included date of ART initiation, AIDS stage
according to US Centers for Disease Control and Prevention
(CDC) classification, hepatitis C virus serological status at
inclusion, type and duration of all antiretroviral treatments
received since initiation, initial and current CD4 cell count and
viral load, nadir CD4 cell count and body mass index (BMI) at
inclusion in the cohort. All these variables were extracted from the
ANRS 1215 cohort data base.
Control subjects were recruited at home in 9 districts of the city
of Dakar and its outskirts, defined according to the place of
residence of the patients. In each district, controls were recruited
randomly as long as they could be sex- and age-matched to a
patient from this area. Patients from outside Dakar or its
surrounding were randomly assigned to one of the 9 districts for
the purpose of control selection. The response rate for recruitment
of control subjects was 54%.
Considering the low prevalence of HIV in Dakar and its
surroundings (,1%), controls were presumed to be HIV-negative
[16].
Clinical evaluation
Data documenting risk factors for low bone mineral density were
collected during a face-to-face interview for both patients and
controls. They included previous fracture, prior fracture in a first-
degree relative, smoking status, alcohol consumption, corticosteroid
use, medical history of specific pathologies (rheumatoid arthritis,
secondary osteoporosis) and menopausal status. In patients, medical
information was validated by clinicians. Calcium intake was
assessed by a 7-day semi-quantitative food frequency questionnaire
that included 17 calcium-rich food items commonly consumed in
Dakar [17]. Physical activity was assessed by a short frequency
questionnaire (‘regular physical activity’ was defined as moderate
activity each day and strenuous activity at least once a month).
Weight and height were measured during the interview to
calculate BMI=weight (kg)/height(m)
2.
QUS bone mineral density
Bone mineral density was assessed using a heel ultrasonic gel-
coupled QUS system, the Pegasus Prestige ultrasonometer
(Osteomed, DMS, France). The Pegasus Prestige ultrasound device
measures two parameters at mid-calcaneus: bone ultrasound
attenuation (BUA) (in dB/MHz) and speed of sound (in m/s).
Three repeated measurements with repositioning were performed
on the same foot for all participants. The in vivo coefficient of
variation for BUA was 3.3% in patients and 3.7% in controls.
BUA was then expressed as T-score (standard deviations from
the mean value in normal young individuals of the same sex) or Z-
score (standard deviations from the mean in individuals of the
same age and sex) using the manufacturer’s age- and sex-specific
reference data for a Caucasian population.
Ethics statement
The Senegalese ethics committee, or Comite ´ National d’E ´thi-
que pour la Recherche en Sante ´ (CNERS), Direction de la Sante ´,
Ministe `re de la Sante ´ et de la Pre ´vention, Dakar, Se ´ne ´gal,
approved the study and all participants gave informed consent.
Authorizations from the committee were obtained separately for
the cohort (patients) in April 2009 and for controls in September
2010. Patients signed an informed consent form at the time of
inclusion in the cohort. Control participants signed an informed
consent form when the survey was conducted in 2010.
Statistical analysis
Comparison of patients included and not included in the study
were made using Student’s t-test for normally distributed contin-
uous variables and Mann-Whitney-U test for continuous variables
not normally distributed, using the x
2-test for categorical variables.
Comparison of characteristics in patients and control subjects
were made using logistic and linear models. We accounted for the
matched-pairs design by introducing the pair-ID as a fixed effect
in the models.
To assess whether T-score (outcome variable for bone density
assessment) differed between patients and controls, we built a first
multivariate linear model with the T-score being the dependent
variable; independent variables were those that met the criterion of
P,0.20inbivariate analysis forassociation with theT-score (i.e. BMI
and physical activity). We then built a second model which included,
in addition, variables not associated with T-score (at a P-value
threshold of 0.20), but which differed between patients and controls
(i.e. calcium intake and smoking). A sex-related effect modification
was investigated through interaction terms in the multivariate model.
To identify factors associated with T-score among patients, we
built a multivariate model including variables that met the
QUS Bone Mineral Density and HIV in Senegal
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31726criterion of P,0.20 in bivariate analysis for association with the T-
score. Since only 3 patients reported alcohol consumption and
none reported rheumatoid arthritis, secondary osteoporosis or
exposure to glucocorticoids, these risk factors for low bone mineral
density or osteoporosis were not presented or included in analyses.
All statistical analyses were performed using Stata software
(version 10.1, Stata Corp, College Station, TX, USA). Tests were
considered statistically significant for P,0.05.
Results
Clinical characteristics of HIV-infected patients
218 out of 267 eligible patients were enrolled in the present
study and 207 patients were finally included in the analysis.
Reasons for non-inclusion were pregnancy (n=5) or missing data
for the patient him/herself or his/her control counterpart (n=6).
Compared with patients included in the analysis, non-enrolled or
non-analyzed patients were more likely to be male (58.3% vs
35.3%; P=0.001) and to have received PI (60.0% vs 44.9%;
P=0.04) or tenofovir disoproxyl fumarate (TDF) (43.3% vs.
26.6%; P=0.01).
Seventy-five percent of patients had been receiving antiretro-
viral treatment for at least 8 years (Table 1). At the time of the
study, 70% were receiving two NRTIs and one NNRTI; 20%
received two NRTIs in association with a PI and 10% were on
bitherapy (TDF and one NNRTI). The current median HIV viral
load was 1.7 (range: 1.6;6.7) log copies/mL and 84% of patients
were undetectable.
Table 1. QUS bone mineral density and lifestyle factors according to HIV status and clinical characteristics of HIV-infected patients.
HIV+ patients
n=207
Controls
n=207 P
Bone mineral density
BUA, mean 6 SD dB/MHz 64.0 67.0 66.0 67.9 0.003
T-score, mean 6 SD 20.70 61.23 20.34 61.39 0.003
Z-score, mean 6 SD 20.22 61.21 0.14 61.39 0.003
Age, mean years 6 SD 46.8 68.4 46.8 68.6 -
Female sex 134 (67.7) 134 (67.7) -
BMI, mean kg/m
2 6 SD 22.9 64.6 26.4 66.4 ,0.0001
Underweight ,18.5 kg/m
2 34 (16.4) 16 (7.7)
Normal $18.5 and ,25 kg/m
2 113 (54.6) 82 (39.6) ,0.0001
Overweight $25 and ,30 kg/m
2 45 (21.7) 54 (26.1)
Obese $30 kg/m
2 15 (7.3) 55 (26.6)
Calcium intake, mean mg/jour 6 SD 457 6334 344 6296 0.0005
Current smoker 8 (3.9) 22 (10.6) 0.002
History of fracture 4 (1.9) 4 (1.9) 1
Regular physical activity 54 (26.1) 55 (26.6) 0.9
Post-menopausal 45/134 (33.6) 43/134 (32.1) 0.7
BMI at treatment initiation, mean kg/m
2 6 SD 20.7 63.7 -
HCV Ab 12 (5.8) -
CDC C-stage 113 (54.6) -
ART duration, median years (IQR) 8.8 (8.0–10.0) -
PI -
Never 114 (55.1) -
Past use 57 (27.5) -
Current 36 (17.4) -
Duration, median months (IQR) 4.9 (3.9–6.3) -
TDF -
Never 152 (73.4) -
Past use 10 (4.8) -
Current use 45 (21.8) -
Duration, median months (IQR) 2.5 (1.5–2.8) -
Current CD4 cell count, median cells/mL (IQR) 496 (351–694) -
CD4 cell count nadir ,100 cells/mL 81 (39.1) -
Current HIV viral load ,50 copies/mL 174 (84.1) -
Note: Data are no. (%) unless otherwise indicated.
BUA, bone ultrasound attenuation; SD, standard deviation; BMI, body mass index; HCV Ab, hepatitis C virus serological status; ART, antiretroviral treatment; IQR,
interquartile range; PI, protease inhibitor; TDF, tenofovir disoproxyl fumarate.
doi:10.1371/journal.pone.0031726.t001
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The 207 patients were compared to 207 age- and sex-matched
controls from the general population. HIV-infected patients had
lower mean BUA and mean T-score than controls (T-score
difference: 20.3660.12; 95% confidence interval (CI), 20.59;
20.12) (Table 1). Although T-scores in men were lower than in
women (20.7561.26 vs 20.4061.35; P,0.0001), differences
between patients and controls in the two sexes were of similar
magnitude (20.38; CI: 20.68;20.08 and 20.32; CI: 20.71; 0.07
for women and men, respectively) (Figure 1).
Comparison between patients and controls for risk factors of low
T-score indicated that BMI was much lower in patients (Table 1).
Participants with a BMI ,18.5 kg/m
2 (underweight) were found
twice as frequently among patients (16%) as among controls (8%).
Female patients and controls had significantly higher mean BMIs
than males, with considerable prevalence of overweight-obesity (37
and 67% for patient and control females, respectively, compared
to 15 and 26% in men). Patients had a higher mean calcium intake
per day and smoked less. History of fracture, physical activity and
proportion of post-menopausal women was similar between
groups.
After adjusting for factors that met the criterion of P,0.20 in
bivariate analysis, i.e. BMI and physical activity, the estimated T-
score difference between patients and controls was 20.25 (CI:
20.50; 0.003) and significance was borderline (P=0.053).
Additional adjustment for smoking and calcium intake led to
similar results (difference: 20.27; CI: 20.53; 20.002; P=0.048).
Comparison of models including or not BMI indicated that the
difference in BMI according to HIV status explained 27% of the
difference in T-scores between groups.
Factors associated with QUS bone mineral density in HIV-
infected patients
In bivariate analyses, factors associated with lower T-score
included older age, lower current BMI and lower BMI at treatment
initiation. PI use in the past, the CD4 nadir ,100 cells/mLa n d
current viral load .50 copies/mL were also associated with a lower
T-score without reaching statistical significance (Table 2). In
multivariate analysis, the T-score was positively and independently
associated with current BMI. BMI at treatment initiation was not
included in the multivariate model because it co-varied with BMI.
However, when tested separately, it was also independently
associated with the T-score, although the association was weaker
compared to current BMI (data not shown). The final model also
suggested that undetectable viral load was associated with a higher
T-score. Current or past use of PI or TDF did not show any
independent association with the T-score. Additional analyses
indicated that patients who had received PI were more frequently in
the CDC C-stage (71.0%in the ever-received group vs 41.2% in the
never-received group; P,0.001), more frequently had a CD4 cell
count nadir ,100 cells/mL (58.1% vs 23.7%; P,0.001) and had a
lower current CD4 cell count (median: 452, IQR: [316–645] vs 536
[386–781] cells/mL; P=0.008).
Discussion
Our findings indicate that Senegalese HIV-infected patients
from the ANRS 1215 cohort had lower heel QUS bone mineral
density than age-and sex-matched controls from the general
population in Dakar. The crude T-score difference observed
between patients and controls was a 20.35 standard deviation. In
other studies comparing HIV-infected to uninfected individuals,
the T-score difference between groups (infected/uninfected) varied
from 20.25 to 21 [18,19,20,21,22,23,24].
We showed that the difference in QUS bone mineral density
was, in part, related to the difference in BMI between patients and
controls. About a third of the difference in bone mineral density
was explained by a difference in corpulence. This observation is in
agreement with Bolland et al., who suggested that the relationship
between HIV infection and low bone density was mediated by low
body weight [25]. Indeed, bone mass is known to be positively
correlated with body weight or BMI, as an indicator of muscular
mass, and HIV-infected individuals usually have lower body
weight compared with uninfected persons [26]. Based on a meta-
analysis, Bolland et al. showed that, after adjustment for body
weight, residual between-group differences in bone mineral density
were small (2.2–4.7%) and unlikely to be clinically significant.
Similarly, a recent study conducted among veterans in the United
States indicated that men with HIV infection were at increased
risk of fragility fractures compared with uninfected men. However,
those authors showed that this excess of risk was almost completely
attributable to lower BMI among infected men [4].
Most studies comparing African-American and white American
men and women have indicated higher bone mineral density in
African-Americans; however, it is not clear whether this difference
can be attributed to differences in BMI between the two groups
[27,28,29]. Bone status is poorly documented in resource-limited
settings like Sub-Saharan Africa. A few studies suggested that bone
mineral density in Africa may be similar to northern world
observations, but the prevalence of fracture appears to be much
lower [30,31,32]. In our study, the mean Z-score observed in the
control group was close to 0 (20.08). This means that the
distribution of crude BUA measurements in the control Senegalese
group was fairly similar to that of reference Caucasian data
provided by the manufacturer.
Most longitudinal studies involving ART-naive individuals
showed that bone density declined by 2 to 6% within 24 to 48
weeks after ART initiation [33,34,35,36]. Thereafter, bone
mineral density values remained stable or even increased slightly
[37,38]. We did not find any association between QUS bone
mineral density and duration of treatment in our study. This could
be due to the fact that all patients had received at least 5 years of
Figure 1. Mean QUS bone mineral density expressed as T-score
(and 95% confidence interval) in HIV-infected patients and
controls, separately for men and women.
doi:10.1371/journal.pone.0031726.g001
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reported significantly greater bone loss in patients who began
tenofovir-based therapy compared with other regimens [36,39,40].
The impact of PI on bone loss remains unclear. While some
studies found that PI increased the risk of low bone mineral density
[23,35,41,42], others did not confirm these results [18,20,43]. In
the present study, patients receiving or having received IP-based
treatment tended to have lower T-scores compared with patients
who were never treated with PI. However, PI-treated patients
were also more likely to have lower nadir CD4 cell counts and
lower current CD4 cell counts, and were likely to be at a more
advanced stage of the disease. Multivariate analysis did not
confirm an independent association between PI and T-score,
indicating that PI use was more likely a marker of disease severity.
Incidentally, a trend toward an association between viral load and
T-score was found. Undetectable patients had higher T-scores
than patients above the threshold of 50 copies per mL. The
interpretation of this association is not clear. To our knowledge,
only two studies had previously observed an association between
high viral load and reduced bone mineral density, suggesting a
potential role for the virus itself [44,45]. In contrast, another study
reported an inverse relationship; low viral load was associated with
reduced bone mineral density [46].
We have shown, in an African setting, that HIV-infected
patients have reduced QUS bone mineral density in comparison
with subjects from the general population. However, the clinical
significance of this result in terms of osteoporosis remains
unknown, since we could not use the validated reference method
for bone density assessment. The World Health Organization
criteria for defining osteoporosis and osteopenia based on T-score
is valid only for measurement of bone mineral density performed
with DXA, and application of these criteria to QUS methodology
is not currently recommended by the International Society of
Clinical Densitometry [11]. Prospective studies of fracture risk
prediction and cross-sectional equivalence studies need to be
implemented in African settings to fully validate use of these
alternative technologies for clinical purposes and osteoporosis
management.
Finally, selection bias in the composition of both patient and
control groups should be taken into account. Patients in the study
cohort were those who had survived and who were able to go to
the hospital for their consultation. They may have been more
Table 2. Bivariate and multivariate regression analyses of factors associated with T-score in HIV-infected patients.
Characteristic Bivariate Multivariate
b
a 95% CI P b
a 95% CI P
Age (/10 years) 20.26 [20.45;20.06] 0.012 20.19 [20.40;0.01] 0.07
Female sex 0.32 [20.03;0.67] 0.076 20.04 [20.41:0.33] 0.83
Current BMI (kg/m
2)
b 0.10 [0.06;0.13] ,0.001
Underweight ,18.5 kg/m
2 Ref. Ref.
Normal $18.5 and ,25 kg/m
2 0.63 [0.18;1.08] 0.007 0.57 [0.12;1.02] 0.01
Overweight $25 and ,30 kg/m
2 1.23 [0.70;1.75] ,0.0001 1.19 [0.66;1.73] ,0.0001
Obese $30 kg/m
2 1.19 [0.47;1.90] 0.001 1.13 [0.40;1.87] 0.003
BMI at treatment initiation kg/m
2c 0.08 [0.03;0.12] 0.001
Calcium intake (/100 mg/day) 20.014 [20.06;0.04] 0.6
Current smoker 20.05 [20.93;0.82] 0.9
History of fracture 20.25 [21.48;0.98] 0.7
Regular physical activity 0.32 [20.06;0.70] 0.10 0.31 [20.07;0.68] 0.11
HCV Ab 0.12 [20.60;0.84] 0.8
CDC C-stage 20.13 [20.47;0.21] 0.5
ART duration (years) 20.02 [20.13;0.08] 0.7
PI
Never Ref. Ref.
Past use 20.35 [20.74;0.04] 0.08 20.09 [20.48;0.30] 0.66
Current use 20.30 [20.76;0.17] 0.21 20.18 [20.64;0.28] 0.44
TDF
Never Ref.
Past use 20.04 [20.84;0.75] 0.91
Current use 20.06 [20.48;0.35] 0.76
Current CD4 cell count (/100 cells/mL) 0.03 [20.03;0.09] 0.28
CD4 cell count nadir ,100 cells/mL 20.34 [20.67;0.00] 0.053 20.27 [20.61;0.08] 0.13
Current HIV viral load ,50 copies/mL 0.44 [20.03;0.90] 0.067 0.48 [0.02;0.93] 0.04
BMI, body mass index; HCV Ab, hepatitis C virus serological status; ART, antiretroviral treatment; PI, protease inhibitor; TDF, tenofovir disoproxyl fumarate.
ab-coefficients ,0 indicate an inverse association between the characteristic and T-score.
bCurrent BMI was kept as a categorical variable in the multivariate model because of non-linearity.
cBMI at treatment initiation was excluded from the multivariate model, as it covaried with current BMI (Pearson’s correlation coefficient: 0.64).
doi:10.1371/journal.pone.0031726.t002
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mineral density. In the control group, participants were volunteers,
and it can be speculated that those who agreed to take part in the
study may have been healthier than those who refused to
participate.
Conclusions
We have shown for the first time, in a resource-limited setting,
that HIV-infected patients on antiretroviral therapy exhibit lower
bone mineral density than their uninfected counterparts. Howev-
er, this reduced bone density is partly explained by lower BMI,
suggesting that BMI may mediate the relationship between HIV
infection and bone mineral density. Further investigation is needed
to establish the clinical significance of these observations.
Meanwhile, we hypothesize that starting antiretroviral therapy
earlier will reduce the impact on bone by limiting the adverse
effects of the infection on weight loss and nutritional status.
Acknowledgments
We acknowledge Amady Ndiaye-Sarr for contribution to data collection,
supervision of field activities and data entry. Thanks go to Sokhna Boye
and Sophie Fall for contribution to data collection, to Solia Adriouch for
help with elaborating the questionnaire and preparation of the study and to
Jacques Gardon for lending us the osteodensitometry device. We are most
grateful to all patients and controls for their participation in the study and
to the entire staff of the Regional Research and Training Center for HIV/
AIDS and that of the Ambulatory Care Unit in Dakar for their help and
collaboration. The ANRS 1215 Study group includes I. Ndoye (Multi-
sectorial AIDS Program, Dakar, Senegal); P. de Beaudrap, E. Delaporte, J.
F. Etard, C. Laurent, B. Taverne (UMI 233, Institut de Recherche pour le
De ´veloppement (IRD)/University Montpellier 1, Montpellier, France); M.
M. Bite `ye, A. B. Dieng, A. Diouf, A. Sarr, L. Zie ´ (Regional Research and
Training Center for HIV/AIDS, Fann University Teaching Hospital,
Dakar, Senegal); V. Cilote, I. Lanie `ce (French Ministry of Foreign Affairs,
Dakar, Senegal); I. Ndiaye, A. Ndir, C. T. Ndour, C. S. Senghor, P. S. Sow
(Department of Infectious Diseases, Fann University Teaching Hospital,
Dakar, Senegal); M. Basty Fall, N. M. Dia Badiane, N. Diakhate ´, M.
Diallo, L. M. Diouf, N. F. Ngom Gue `ye (Ambulatory Care Unit-Red-
Cross, Fann University Teaching Hospital, Dakar, Senegal); K. Ba Fall, P.
M. Gue `ye, C. Pe ´rino (Military Hospital of Dakar, Senegal); P. A. Diaw, H.
Diop Ndiaye, S. Mboup, N. C. Toure ´ Kane (Le Dantec University
Teaching Hospital, Virology and Bacteriology Laboratory, Dakar,
Senegal); K. Sow (AIDS Control Division, Ministry of Health, Dakar,
Senagal); K. Diop, B. Ndiaye (Central Pharmacy, Fann University
Teaching Hospital, Dakar, Senegal); M. Ciss (Ministry of Health, National
Drug Laboratory, Dakar, Senegal); and A. Desclaux (Paul Cezanne
University, CReCSS, Aix-en-Provence, France).
Author Contributions
Conceived and designed the experiments: AC SED AD KB ED.
Performed the experiments: CM JC NFNG CC. Analyzed the data:
SED AC. Wrote the paper: AC SED AD CM JC NFNG CC BT KB PSS
ED.
References
1. Brown TT, Qaqish RB (2006) Antiretroviral therapy and the prevalence of
osteopenia and osteoporosis: a meta-analytic review. AIDS 20: 2165–2174.
2. McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, et al. (2010) Bone
disease in HIV infection: a practical review and recommendations for HIV care
providers. Clin Infect Dis 51: 937–946.
3. Triant VA, Brown TT, Lee H, Grinspoon SK (2008) Fracture prevalence among
human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients
in a large U.S. healthcare system. J Clin Endocrinol Metab 93: 3499–3504.
4. Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, et al. (2011) Increased
risk of fragility fractures among HIV infected compared to uninfected male
veterans. PLoS One 6: e17217.
5. Guglielmi G, Scalzo G, de Terlizzi F, Peh WC (2010) Quantitative ultrasound in
osteoporosis and bone metabolism pathologies. Radiol Clin North Am 48:
577–588.
6. Hans D, Dargent-Molina P, Schott AM, Sebert JL, Cormier C, et al. (1996)
Ultrasonographic heel measurements to predict hip fracture in elderly women:
the EPIDOS prospective study. Lancet 348: 511–514.
7. Hans D, Durosier C, Kanis JA, Johansson H, Schott-Pethelaz AM, et al. (2008)
Assessment of the 10-year probability of osteoporotic hip fracture combining
clinical risk factors and heel bone ultrasound: the EPISEM prospective cohort of
12,958 elderly women. J Bone Miner Res 23: 1045–1051.
8. Khaw KT, Reeve J, Luben R, Bingham S, Welch A, et al. (2004) Prediction of
total and hip fracture risk in men and women by quantitative ultrasound of the
calcaneus: EPIC-Norfolk prospective population study. Lancet 363: 197–202.
9. Moayyeri A, Kaptoge S, Dalzell N, Bingham S, Luben RN, et al. (2009) Is QUS
or DXA better for predicting the 10-year absolute risk of fracture? J Bone Miner
Res 24: 1319–1325.
10. Constant D, Rosenberg L, Zhang Y, Cooper D, Kalla AA, et al. (2009)
Quantitative ultrasound in relation to risk factors for low bone mineral density in
South African pre-menopausal women. Arch Osteoporos 4: 55–65.
11. Krieg MA, Barkmann R, Gonnelli S, Stewart A, Bauer DC, et al. (2008)
Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD
Official Positions. J Clin Densitom 11: 163–187.
12. Desclaux A, Ciss M, Taverne B, Sow PS, Egrot M, et al. (2003) Access to
antiretroviral drugs and AIDS management in Senegal. AIDS 17 Suppl 3:
S95–101.
13. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, et al. (2006)
Mortality and causes of death in adults receiving highly active antiretroviral
therapy in Senegal: a 7-year cohort study. AIDS 20: 1181–1189.
14. Laurent C, Diakhate N, Gueye NF, Toure MA, Sow PS, et al. (2002) The
Senegalese government’s highly active antiretroviral therapy initiative: an 18-
month follow-up study. AIDS 16: 1363–1370.
15. Landman R, Poupard M, Diallo M, Ngom Gueye NF, Diakhate N, et al. (2009)
Tenofovir-emtricitabine-efavirenz in HIV-I-infected adults in Senegal: a 96-
week pilot trial in treatment-naive patients. J Int Assoc Physicians AIDS Care
(Chic) 8: 379–384.
16. Ndiaye S, Ayad M (2005) Senegal Demographic and Health Survey 2005.
Dakar, Senegal: Ministry of Health and Prevention.
17. Dop M-C, Gomis M-C, Gourdon M, Lesauvage S (2003) Outils
d’enque ˆte alimentaire par entretien - Elaboration au Se ´ne ´gal. Paris: IRD
Editions.
18. Amiel C, Ostertag A, Slama L, Baudoin C, N’Guyen T, et al. (2004) BMD is
reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 19:
402–409.
19. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, et al. (2007)
Decreased bone mineral density and increased fracture risk in aging men with or
at risk for HIV infection. AIDS 21: 617–623.
20. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Santoro N, et al. (2006)
HIV infection and bone mineral density in middle-aged women. Clin Infect Dis
42: 1014–1020.
21. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J (2003) Decreased
bone mineral density in HIV-infected patients is independent of antiretroviral
therapy. AIDS 17: 1917–1923.
22. Dolan SE, Kanter JR, Grinspoon S (2006) Longitudinal analysis of bone density
in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 91:
2938–2945.
23. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, et al. (2000)
Accelerated bone mineral loss in HIV-infected patients receiving potent
antiretroviral therapy. AIDS 14: F63–67.
24. Yin M, Dobkin J, Brudney K, Becker C, Zadel JL, et al. (2005) Bone mass and
mineral metabolism in HIV+ postmenopausal women. Osteoporos Int 16:
1345–1352.
25. Bolland MJ, Grey AB, Gamble GD, Reid IR (2007) Low body weight mediates
the relationship between HIV infection and low bone mineral density: a meta-
analysis. J Clin Endocrinol Metab 92: 4522–4528.
26. Reid IR (2002) Relationships among body mass, its components, and bone.
Bone 31: 547–555.
27. Finkelstein JS, Brockwell SE, Mehta V, Greendale GA, Sowers MR, et al. (2008)
Bone mineral density changes during the menopause transition in a multiethnic
cohort of women. J Clin Endocrinol Metab 93: 861–868.
28. Melton IL, Marquez MA, Achenbach SJ, Tefferi A, O’Connor MK, et al. (2002)
Variations in bone density among persons of African heritage. Osteoporos Int
13: 551–559.
29. Nam HS, Shin MH, Zmuda JM, Leung PC, Barrett-Connor E, et al. (2010)
Race/ethnic differences in bone mineral densities in older men. Osteoporos Int
21: 2115–2123.
30. Aspray TJ, Prentice A, Cole TJ, Sawo Y, Reeve J, et al. (1996) Low bone
mineral content is common but osteoporotic fractures are rare in elderly rural
Gambian women. J Bone Miner Res 11: 1019–1025.
31. Vanderjagt DJ, Bond B, Dulai R, Pickel A, Ujah IO, et al. (2001) Assessment of
the bone status of Nigerian women by ultrasound and biochemical markers.
Calcif Tissue Int 68: 277–284.
QUS Bone Mineral Density and HIV in Senegal
PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e3172632. Zebaze RM, Seeman E (2003) Epidemiology of hip and wrist fractures in
Cameroon, Africa. Osteoporos Int 14: 301–305.
33. Briot K, Kolta S, Flandre P, Boue F, Ngo Van P, et al. (2011) Prospective one-
year bone loss in treatment-naive HIV+ men and women on single or multiple
drug HIV therapies. Bone 48: 1133–1139.
34. Brown TT, McComsey GA (2010) Association between initiation of antiretro-
viral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther
15: 425–429.
35. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, et al. (2009) Greater
decrease in bone mineral density with protease inhibitor regimens compared
with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected
naive patients. AIDS 23: 817–824.
36. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, et al. (2004)
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in
antiretroviral-naive patients: a 3-year randomized trial. JAMA 292: 191–201.
37. Bolland MJ, Wang TK, Grey A, Gamble GD, Reid IR (2011) Stable Bone
Density in HAART-Treated Individuals with HIV: A Meta-Analysis. J Clin
Endocrinol Metab 96: 2721–2731.
38. Cassetti I, Madruga JV, Suleiman JM, Etzel A, Zhong L, et al. (2007) The safety
and efficacy of tenofovir DF in combination with lamivudine and efavirenz
through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials
8: 164–172.
39. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, et al. (2011) Bone
mineral density and fractures in antiretroviral-naive persons randomized to
receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine
along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group
A5224s, a substudy of ACTG A5202. J Infect Dis 203: 1791–1801.
40. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, et al. (2010)
Comparison of changes in bone density and turnover with abacavir-lamivudine
versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the
ASSERT study. Clin Infect Dis 51: 963–972.
41. Calmy A, Fux CA, Norris R, Vallier N, Delhumeau C, et al. (2009) Low bone
mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-
sectional study. J Infect Dis 200: 1746–1754.
42. Fernandez-Rivera J, Garcia R, Lozano F, Macias J, Garcia-Garcia JA, et al.
(2003) Relationship between low bone mineral density and highly active
antiretroviral therapy including protease inhibitors in HIV-infected patients.
HIV Clin Trials 4: 337–346.
43. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, et al. (2009)
Loss of bone mineral density after antiretroviral therapy initiation, independent
of antiretroviral regimen. J Acquir Immune Defic Syndr 51: 554–561.
44. Fausto A, Bongiovanni M, Cicconi P, Menicagli L, Ligabo EV, et al. (2006)
Potential predictive factors of osteoporosis in HIV-positive subjects. Bone 38:
893–897.
45. Fessel WJ, Hurley LB (2003) Is HIV sequestered in bone? Possible implications
of virological and immunological findings in some HIV-infected patients with
bone disease. AIDS 17: 255–257.
46. Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, et al.
(2008) Reduced bone mineral density in HIV-infected patients: prevalence and
associated factors. AIDS 22: 395–402.
QUS Bone Mineral Density and HIV in Senegal
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e31726